Selection of chemotherapy by ex vivo assessment of tumor sensitivity to cytotoxic drugs: Results of a clinical trial

Medical Oncology

Volumn 19, Issue 3, 2002, Pages 151-159

  Berglund, Åke ^a   Glimelius, Bengt ^a   Bergh, Jonas ^a,c   Brodin, Ola ^a,d   Fjällskog, Marie Louise ^a   Hagberg, Hans ^a   Von Heideman, Anne ^a   Larsson, Rolf ^a   Tholander, Bengt ^a,c   De la Torre, Manuel ^a   Åström, Gunnar ^a   Öberg, Kjell ^a   Parö, Gunnar ^b   Nygren, Peter ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b BRISTOL MYERS SQUIBB   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Chemotherapy; Cremophor EL; Ex vivo assay; Solid tumor; Taxol

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; AMSACRINE; ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; IDARUBICIN; IRINOTECAN; MELPHALAN; MITOMYCIN C; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; TIOGUANINE; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONTROLLED STUDY; DRUG CHOICE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ADOLESCENT; CANCER STAGING; CELL CULTURE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG RESISTANCE; DRUG SCREENING; METHODOLOGY; MIDDLE AGED; MORTALITY; NEOPLASM; PREDICTION AND FORECASTING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PACLITAXEL; PREDICTIVE VALUE OF TESTS;

EID: 18744382727     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:19:3:151     Document Type: Article

References (30)

1. Fruehauf, J.P. and Bosanquet, A.G. (1993). In vitro determination of drug response: A discussion of clinical applications. PPO Updates 7:1-16.
2. Larsson, R. and Nygren, P. (1993). Laboratory prediction of clinical chemotherapeutic drug resistance: A working model exemplified by acute leukemia. Eur. J. Cancer 29A:1208-1212.
3. Gurney, H. (1996). Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J. Clin. Oncol. 14:2590-2611.
4. Sandström, M., et al. (1996). Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin and 4-hydroxocyclophosphamide regimen in breast cancer patients. J. Clin. Oncol. 14:1581-1588.
5. Hammond, M.E., et al. (2000). College of American Pathologists Conference XXXV: Solid tumor prognostic factors - Which, how and so what? Arch. Pathol. Lab. Med. 124:958-965.
6. Bergh, J., et al. (2000). Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Lancet 356:1384-1391.
7. Nygren, P. (2001). What is cancer chemotherapy. Acta Oncol. 40:166-174.
8. Weisenthal, L. and Lippman, M. (1985). Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat. Rep. 69:615-632.
9. Weisenthal, L. and Nygren, P. (2002). Current status of cell culture drug resistance testing (CCDRT). Oncology, in press.
10. Larsson, R., Nygren, P., Ekberg, M. and Slater, L. (1990). Chemotherapeutic drug sensitivity testing of human leukemia cells in vitro using a semiautomated fluorometric assay. Leukemia 4:567-571.
11. Nygren, P., et al. (1994). Detection of tumor specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int. J. Cancer 56:715-720.
12. Nygren, P., et al. (1994). In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin's lymphoma using the fluorometric microculture cytotoxicity assay (FMCA). Ann. Oncol. 5:127-131.
13. Csoka, K., Tholander, B., Gerdin, E., Larsson, R. and Nygren, P. (1997). In vitro determination of cytotoxic drug-response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer 72:1008-1012.
14. Rowinsky, E.K., Onetto, N., Canetta, R.M. and Arbuck, S.G. (1992). Taxol: The first of the taxanes, an important new class of antitumor agents. Semin. Oncol. 19:646-662.
15. Kälkner, M., et al. (1994). Diagnostics of malignant lymphomas with ultrasound guided 1.2 mm biopsy-gun. Acta Oncol. 33:33-37.
16. Csoka, K., et al. (1994). Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol. Oncol. 54:163-170.
17. Larsson, R., Kristensen, J., Sandberg, C. and Nygren, P. (1992). Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA). Int. J. Cancer 50:177-185.
18. Fridborg, H., Nygren, P. and Larsson, R. (1995). Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs. Anti-Cancer Drugs 6:64-69.
19. Larsson, R. and Nygren, P. (1993). Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model. Anticancer Res. 13:1825-1830.
20. Miller, A.B., Hoogstraten, B., Staquet, M. and Winkler, A. (1981). Reporting results of cancer treatment. Cancer 47:207-214.
21. Cortazar, P. and Johnson, B.E. (1999). Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J. Clin. Oncol. 17:1625-1631.
22. Nygren, P., et al. (1992). Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 6:1121-1128.
23. Weisenthal, L. (1991). Predictive assays for drug and radiation resistance, in Human Cancer in Primary Culture, a Handbook (J. Masters, eds), pp. 103-107, Kluwer Academic, Dordrecht.
24. Schuurhuis, G.J., et al. (1990). The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br. J. Cancer 62:591-594.
25. Webster, L., et al. (1993). Measurement of Cremophor EL following Taxol: Plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J. Natl. Cancer Inst. 85:1685-1690.
26. Millward, M.J., et al. (1998). Phase I trial of Cremophor EL with bolus doxorubicin. Clin. Cancer Res. 4:2321-2329.
27. Nygren, P., et al. (1995). The cytotoxic effect of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. Br. J. Cancer 71:478-481.
28. Sparrebom, A., et al. (1998). Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo. Clin. Cancer Res. 4:1937-1942.
29. Pieters, R., et al. (1991). Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia. Lancet 338:399-403.
30. Konecny, G., et al. (2000). Correlation of drug response with the ATP tumour chemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol. Oncol. 77:258-263.